The FDA has approved Teva's (TEVA -0.6%) Synribo to treat adults with chronic myelogenous...
Friday, October 26, 2012, 10:51 AM ETThe FDA has approved Teva's (TEVA -0.6%) Synribo to treat adults with chronic myelogenous leukemia, a blood and bone marrow disease. The drug is intended to be used in patients whose cancer progressed after treatment with at least two drugs from a class called tyrosine kinase inhibitors, also used to treat the disease.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles